Low-grade inflammation has been recognized as an important feature of atherosclerosis (1 ); therefore, markers of inflammation have been investigated for risk estimation of cardiovascular events (2, 3 ) . However, in lowgrade inflammations, C-reactive protein (CRP) concentrations are often lower than the measuring range of traditional CRP assays. For this purpose new assays, so-called high-sensitivity CRP (hs-CRP) assays, have been developed that cover a measuring range two orders of magnitude lower than those of the traditional assays (4 ) . On the basis of hs-CRP results obtained in several cohort studies (5) (6) (7) (8) , an algorithm using hs-CRP and lipid values was recently proposed for cardiovascular risk assessment (9 ) .
The aim of the present study was to evaluate four turbidimetric assays, suited for clinical chemistry analyzers, for analytical performance within the concentration range 0.7-3.9 mg/L, which has been proposed for cardio- vascular risk assessment (9 ) , in comparison with an established nephelometric assay.
For precision and linearity studies we prepared serum pools from blood samples with previously measured hs-CRP (BN II nephelometer; Dade-Behring). The low and high pools were prepared by combining samples with hs-CRP Ͻ1 mg/L and 5-6 mg/L, respectively. The high pool was diluted with the low pool to the following final percentages of high pool: 100%, 75%, 50%, 30%, 20%, 10%, 5%, and 0%. The dilutions were aliquoted and stored at Ϫ20°C for a maximum period of 3 weeks until use. All five hs-CRP methods were used according to the manufacturers' instructions. The Dade-Behring assay was performed on a BN II nephelometer (Dade-Behring), and the turbidimetric assays provided by Roche, Technoclone, Orion, and Biokit were performed on a Hitachi 911 (Roche).
To examine the precision of the five methods in the hs-CRP concentration range Ͻ0.7 to Ն3.9 mg/L, which has been proposed for cardiovascular risk estimation using the nephelometric assay (9 ), aliquots of serum pool dilutions were measured in duplicate on 8 different days (Table 1) . CVs were Յ2.6% for the Roche method, Յ3.8% for the Technoclone, Յ4.7% for the Dade-Behring, and Յ6.5% for the Biokit. The Orion method showed CVs Յ5.1% above 1 mg/L, but CVs of 11-21% between 1 and 0.5 mg/L. The imprecision (CV) of the investigated turbidimetric assays other than Orion was comparable to that of the nephelometric assay at critical concentrations. For all pools, the highest values were measured by the Roche method (5.78 -0.82 mg/L) and the lowest by the Technoclone method (4.17-0.34 mg/L).
To study the linearity of the five methods we calculated the target concentrations of pools 2-7 from the measured mean concentrations of pool 1 (100% high pool) and pool 8 (100% low pool). Table 1 shows the calculated target concentrations of the pool dilutions as well as the percentages of deviation of the measured concentrations from the respective target values.
To study the correlation of the turbidimetric methods with the nephelometric method, we collected 101 serum samples from routine requests for traditional CRP analysis [Tinaquant assay (Roche) on the Hitachi Modular-P Unit]: in 80 samples, CRP was Ͻ5 mg/L (detection limit), and in 21 samples, CRP was 5-8 mg/L. The use of leftover material for evaluation of diagnostic methods is in concordance with the European Law for Medical and Diagnostic Products.
The samples were then analyzed with the hs-CRP methods (Fig. 1) . Inspection of Fig. 1 shows a bend in the regression line of the Roche method compared with the Dade-Behring method and a less-pronounced bend for the Technoclone and Biokit methods. From the respective bias plots we located the bend at a hs-CRP concentration of 2.5 mg/L when measured by the Dade-Behring method. This bend might be attributable to the opposite nonlinearity of the Roche, Technoclone, and Biokit assays relative to the Dade-Behring assay as shown in Table 1 . Therefore, for each method two Deming regression equations (10 ) were calculated: one for data Ͻ2.5 mg/L and one for data Ͼ2.5 mg/L. The slopes below and above 2.5 mg/L were 1.13 and 0.9 for the Roche method, 0.83 and 0.75 for the Technoclone method, 0.97 and 0.82 for the Biokit method, and 0.75 and 0.72 for the Orion method, respectively.
For evaluation of the concordance of results obtained by the nephelometric and turbidimetric assays from the 101 patient samples in the cardiovascular risk assessment, hs-CRP concentrations measured by the turbidimetric assays were harmonized using the respective regression equations calculated for data below and above 2.5 mg/L. The harmonized turbidimetric concentrations thus obtained were again subjected to Deming regression analysis; the calculated slopes were 1.01 (Roche and Orion), 1.00 (Technoclone), and 0.97 (Biokit), and the intercepts were between Ϫ0.02 and Ϫ0.05 mg/L. These harmonized values were then used for risk assessment based on the cutoff values established for the nephelometric assay (9 ) . The best concordance with the nephelometric assay was for the Roche assay (96% of patient samples), followed by the Biokit (92%), Orion (90%), and Technoclone (84%) assays. No patient sample was mismatched for more than one adjacent risk group by any method. In comparison, when the turbidimetric values were harmonized by a single regression equation calculated for the whole data range (without splitting data below and above 2.5 mg/L) the concordance with the nephelometric assay was up to 3% lower.
In conclusion, both the linearity and the correlation study revealed some deficits with respect to the performance and standardization of the hs-CRP assays. For clinical risk stratification, concordance between assays is needed, especially at cutoff values separating risk groups. Turbidimetric hs-CRP assays are suitable for arteriosclerotic risk stratification provided that standardization is improved. Meanwhile, it may be possible to harmonize data from different assays by use of regression equations derived from method comparison studies. 5Ј-Nucleotidase (5Ј-ribonucleotide phosphohydrolase; EC 3.1.3.5; 5NT), an intrinsic membrane glycoprotein present as an ectoenzyme in a wide variety of mammalian cells, hydrolyzes 5Ј-nucleotides to their corresponding nucleosides (1 ). Despite its ubiquitous distribution, serum concentrations of 5NT appear to reflect hepatobiliary disease with considerable specificity (2 ) . Dixon and Purdom (3 ) first observed that serum 5NT was clinically useful for differential diagnosis of hepatobiliary and osseous diseases, the enzyme activity being increased only in hepatobiliary diseases. This finding has been confirmed by several authors (4 -7 ) .
5-Nucleotidase in the
Assay of 5NT activity may have value as an addition to measurement of nonspecific total alkaline phosphatase (AP) in patients with suspected hepatobiliary disease (8 -12 ) , and abnormal 5NT activity is routinely interpreted by some clinicians as evidence of a hepatic origin of increased AP activity in serum. However, a direct
